Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4604-4610

  Ott, Katja ^a   Fink, Ulrich ^a   Becker, Karen ^a   Stahl, Alexander ^a   Dittler, Hans Joachim ^a   Busch, Raymonde ^a   Stein, Hubert ^a   Lordick, Florian ^a   Link, Thomas ^a   Schwaiger, Markus ^a   Siewert, Jörg Rüdiger ^a   Weber, Wolfgang A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GLUCOSE DERIVATIVE; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE; CHI SQUARE DISTRIBUTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PHASE 2 CLINICAL TRIAL; PREDICTION AND FORECASTING; PREOPERATIVE CARE; SCINTISCANNING; STOMACH TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; CISPLATIN; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1542438617     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.574     Document Type: Article

References (51)

1. Findlay M, Young H, Cunningham D, et al: Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 14:700-708, 1996
2. Romer W, Hanauske AR, Ziegler S, et al: Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471, 1998
3. Schelling M, Avril N, Nahrig J, et al: Positron emission tomography using [(18)F]fiuorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
4. Smith IC, Welch AE, Hutcheon AW, et al: Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000
5. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
6. Roder JD, Böttcher K, Siewert JR, et al: Prognostic factors in gastric carcinoma: Results from the german gastric cancer study 1992. Cancer 72:2089-2097, 1993
7. Buchholtz TW, Welch CE, Malt RA: Clinical correlates of resectability and survival in gastric carcinoma. Ann Surg 188:711-715, 1978
8. Siewert J, Feith M, Werner M, et al: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232:353-361, 2000
9. Ajani JA, Mansfield PF, Lynch PM, et al: Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 17:2403-2411, 1999
10. Lowy AM, Mansfield PF, Leach SD, et al: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229:303-308, 1999
11. Chak A, Canto MI, Cooper GS, et al: Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 88:1788-1795, 2000
12. Rang YK, Choi DW, Im YH, et al: A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proc Am Soc Clin Oncol 15:215, 1996 (abstr 503)
13. Songun I, Keizer HJ, Hermans J, et al: Chemotherapy for operable gastric cancer: Results of the Dutch randomized FAMTX trial. Eur J Cancer 25:558-562, 1999
14. Fujii M, Kosaki G, Tsuchiya S, et al: Randomized trial of preoperative adjuvant chemotherapy using oral 5-FU in operable gastric cancer. Proc Am Soc Clin Oncol 18:272a, 1999 (abstr 1045)
15. Sobin L, Wittekind C: TNM Classification of Malignant Tumors (ed 5). New York, NY, Wiley & Sons, 1997
16. Dittler HJ, Fink U, Siewert GR: Response to chemotherapy in esophageal cancer. Endoscopy 26:769-771, 1994
17. Stein HJ, Kraemer SJ, Feussner H, et al: Clinical value of diagnostic laparoscopy with laparoscopic ultrasound in patients with cancer of the esophagus or cardia. J Gastrointest Surg 1:167-173, 1997
18. Helmberger H III, Baum U, Dittler HJ, et al: Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy. Eur J Radiol 23:107-110, 1996
19. Fink U, Ott K, Dittler HJ, et al: Neoadjuvant cisplatinum, leucovorin and fluorouracil (PLF) in adequately staged patients with locally advanced gastric carcinoma. Proc Am Soc Clin Oncol 18:272a, 1999 (abstr 1044)
20. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using F-18-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur J Cancer 35:1773-1782, 1999
21. Siewert JR, Stein HJ, Sendler A, et al: Surgical resection for cancer of the cardia. Semin Surg Oncol 17:125-131, 1999
22. Becker K, Mueller J, Schuhmacher C, et al: Histomorphology and grading of regression in gastric cancer treated with neoadjuvant chemotherapy. Cancer 98:1521-1530, 2003
23. Lauren P: The two histological main types of gastric carcinoma: Diffuse and so called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31-49, 1965
24. Armitage P, Berry G: Statistical Methods in Medical Research (ed 3). Oxford, United Kingdom, Blackwell Scientific, 1994
25. Lenz HJ, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182, 1996
26. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309-316, 1998
27. Ott K, Vogelsang H, Mueller J, et al: Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9:2307-2315, 2003
28. Boku N, Chin K, Hosokawa K, et al: Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cisplatinum. Clin Cancer Res 4:1469-1474, 1998
29. Yeh KH, Shun CT, Chen CL, et al: Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluororacil-based systemic chemotherapy. Hepatogastroenterology 46:610-615, 1999
30. Giatromanolaki A, Stathopoulos GP, Koukourakis MI, et al: Angiogenesis and apoptosis-related protein (p53, bclK-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. Am J Clin Oncol 24:222-226, 2001
31. Kikuyama S, Inada T, Shimizu K, et al: P53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 21:2149-2152, 2001
32. Nooter K, Kok T, Bosman FT, et al: Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy. Eur J Cancer 34:81-86, 1998
33. Stahl A, Ott K, Weber WA, et al: FDG PET imaging of locally advanced gastric carcinomas: Correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288-295, 2003
34. De Potter T, Flamen P, van Cutsem E, et al: Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 29:525-529, 2002
35. Kawamura T, Kusakabe T, Sugino T, et al: Expression of glucose transporter-1 in human gastric carcinoma: Association with tumor aggressiveness, metastasis, and patient survival. Cancer 92:634-641, 2001
36. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al: Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxyglucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases-Leuven Lung Cancer Group. J Clin Oncol 17:3201-3206, 1999
37. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
38. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
39. Spaepen K, Stroobants S, Dupont P, et al: [(18)F]FDG PET monitoring of tumour response to chemotherapy: Does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30:682-688, 2003
40. Couper GW, McAteer D, Wallis F, et al: Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 85:1403-1406, 1998
41. Brucher BL, Weber W, Bauer M, et al: Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron tomography. Ann Surg 233:300-309, 2001
42. Flamen P, van Cutsem E, Lerut A, et al: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361-368, 2002
43. Downey RJ, Akhurst T, Ilson D, et al: Whole body 18-FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 21:428-432, 2003
44. Keyes JW Jr: SUV: Standard uptake or silly useless value? J Nucl Med 36:1836-1839, 1995
45. Weber WA, Ziegler SI, Thodtmann R, et al: Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771-1777, 1999
46. Minn H, Zasadny KR, Quint LE, et al: Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196:167-173, 1995
47. Hoekstra CJ, Hoekstra OS, Stroobants SG, et al: Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43:1304-1309, 2002
48. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastrointestinal junction. N Engl J Med 345:725-730, 2001
49. Ajani JA, Komaki R, Putnam JB, et al: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92:279-286, 2001
50. Roth AD, Maibach R, Martinelli G, et al: Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma-Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301-306, 2000
51. Ajani JA, Baker J, Pisters PW, et al: Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 16:16-18, 2002